Our work is supported by:
German Center for Infection Research (DZIF)
We are funded through the German Center for Infection Research (DZIF) for the development of a SARS Corona vaccine ( link ) and as part of the Working Group "Clinical management and epidemiology of emerging infections" ( link ).
DZIF is one of the six German Centers for Health Research ( DZG ) Deutsche Zentren der Gesundheitsforschung (DZG)
Contact Christine Dahlke, Scientist
German Research Foundation
German Research Foundation / DFG
We are part of the DFG-funded Research Unit for studying sex differences in immunity.
Increasing evidence suggests that common biological pathways regulating immune cell function are involved in sex-specific differences in immunity to self (autoimmune diseases and malignancies) or to foreign (pathogens, vaccines).
Find out more on sex differences in immunity:
Research Unit 5068 | Sex differences in immunity
Contact Tamara Zoran, Scientist
Federal Ministry of Education and Research
The BMBF funds a single center study of the immunogenicity of recombinant Vesicular Stomatitis vaccine for Ebola-Zaire (rVSV∆G-ZEBOV-GP) for pre-exposure prophylaxis in individuals at potential occupational risk for Ebola virus exposure – EU Site Germany (PREPARE-Germany).
Contact Anahita Fathi, Clinician Scientist
CEPI finances the two-center, randomized, double-blind, placebo-controlled, phase Ib study to assess the safety, tolerability and immunogenicity of two ascending doses of the candidate vaccine MVA-MERS-S_DF-1 in healthy study subjects.
Contact Svenja Hardtke, Coordinator
netzwerk universitäts medizin
Research network of university medical centers
Nationales Pandemie Kohorten Netz
The IIRVD conducts Phase I clinical trials in cooperation with the CTC North.